EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate.

Autor: Bibbò S; Department of Innovative Technologies in Medicine & Dentistry, University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy; Center for Advanced Studies and Technology (CAST), University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy., Capone E; Department of Innovative Technologies in Medicine & Dentistry, University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy; Center for Advanced Studies and Technology (CAST), University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy., Lovato G; Department of Innovative Technologies in Medicine & Dentistry, University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy; Center for Advanced Studies and Technology (CAST), University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy., Ponziani S; Department of Life, Health and Environmental Sciences, University of L'Aquila, Coppito, Italy., Lamolinara A; Center for Advanced Studies and Technology (CAST), University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy; Department of Life, Health and Environmental Sciences, University of L'Aquila, Coppito, Italy; Department of Neurosciences, Imaging and Clinical Sciences, University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy., Iezzi M; Center for Advanced Studies and Technology (CAST), University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy; Department of Neurosciences, Imaging and Clinical Sciences, University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy., Lattanzio R; Department of Innovative Technologies in Medicine & Dentistry, University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy; Center for Advanced Studies and Technology (CAST), University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy., Mazzocco K; Laboratory of Experimental Therap ies in Oncology, IRCCS Istituto Giannina Gaslini., Morini M; Laboratory of Experimental Therap ies in Oncology, IRCCS Istituto Giannina Gaslini., Giansanti F; Department of Life, Health and Environmental Sciences, University of L'Aquila, Coppito, Italy., De Laurenzi V; Department of Innovative Technologies in Medicine & Dentistry, University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy; Center for Advanced Studies and Technology (CAST), University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy., Whitfield J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain., Iacobelli S; MediaPharma s.r.l., Via Colonnetta 50/A, Chieti, Italy., Ippoliti R; Department of Life, Health and Environmental Sciences, University of L'Aquila, Coppito, Italy. Electronic address: Rodolfo.ippoliti@univaq.it., Beaulieu ME; Peptomyc S.L., Barcelona 08035, Spain. Electronic address: mbeaulieu@peptomyc.com., Soucek L; Peptomyc S.L., Barcelona 08035, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra 08193, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. Electronic address: lsoucek@vhio.net., Sala A; Centre for Inflammation Research and Translational Medicine (CIRTM); College, of Health, Medicine and Life Sciences, Brunel University London, Uxbridge UB8 3PH, United Kingdom,. Electronic address: arturo.sala@brunel.ac.uk., Sala G; Department of Innovative Technologies in Medicine & Dentistry, University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy; Center for Advanced Studies and Technology (CAST), University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy. Electronic address: g.sala@unich.it.

Publikováno v: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2024 Oct; Vol. 374, pp. 171-180. Date of Electronic Publication: 2024 Aug 14.

MYC: there is more to it than cancer.

Autor: Zacarías-Fluck MF; Models of Cancer Therapies Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Soucek L; Models of Cancer Therapies Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.; Peptomyc S.L., Barcelona, Spain., Whitfield JR; Models of Cancer Therapies Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

Publikováno v: Frontiers in cell and developmental biology [Front Cell Dev Biol] 2024 Mar 06; Vol. 12, pp. 1342872. Date of Electronic Publication: 2024 Mar 06 (Print Publication: 2024).

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Autor: Woo, X.Y., Giordano, J., Srivastava, A., Zhao, Z.-., Lloyd, M.W., de Bruijn, R., Suh, Y.-., Patidar, R., Chen, L., Scherer, S., Bailey, M.H., Yang, C.-., Cortes-Sanchez, E., Xi, Y., Wang, J., Wickramasinghe, J., Kossenkov, A.V., Rebecca, V.W., Sun, H., Mashl, R.J., Davies, S.R., Jeon, R., Frech, C., Randjelovic, J., Rosains, J., Galimi, F., Bertotti, A., Lafferty, A., O'Farrell, A.C., Modave, E., Lambrechts, D., ter Brugge, P., Marangoni, E., El Botty, R., Kim, H., Kim, J.-., Yang, H.-., Lee, C., Dean, D.A., Davis-Dusenbery, B., Evrard, Y.A., Doroshow, J.H., Welm, A.L., Welm, B.E., Lewis, M.T., Fang, B., Roth, J.A., Meric-Bernstam, F., Herlyn, M., Davies, M.A., Ding, L., Li, S., Govindan, R., Isella, C., Moscow, J.A., Trusolino, L., Byrne, A.T., Jonkers, J., Bult, C.J., Medico, E., Chuang, J.H., Robinson, P.N., Sanderson, B.J., Neuhauser, S.B., Dobrolecki, L.E., Zheng, X., Majidi, M., Zhang, R., Zhang, X., Akcakanat, A., Evans, K.W., Yap, T.A., Li, D., Yucan, E., Lanier, C.D., Saridogan, T., Kirby, B.P., M. J., H., Chen, H., Kopetz, S., Menter, D.G., Zhang, J., Westin, S.N., Kim, M.P., Dai, B., Gibbons, D.L., Tapia, C., Jensen, V.B., Boning, G., Minna, J.D., Park, H., Timmons, B.C., Girard, L., Fingerman, D., Liu, Q., Somasundaram, R., Xiao, M., Yennu-Nanda, V.G., Tetzlaff, M.T., Xu, X., Nathanson, K.L., Cao, S., Chen, F., Dipersio, J.F., Lim, K.H., C. X., M., Rodriguez, F.M., Van Tine, B.A., Wang-Gillam, A., Wendl, M.C., Wu, Y., Wyczalkowski, M.A., Yao, L., Jayasinghe, R., Aft, R.L., Fields, R.C., Luo, J., Fuh, K.C., Chin, V., Digiovanna, J., Grover, J., Koc, S., Seepo, S., Wallace, T., Pan, C.-., Chen, M.S., Carvajal-Carmona, L.G., Kirane, A.R., Cho, M., Gandara, D.R., Riess, J.W., Le, T., deVere White, R.W., Tepper, C.G., Zhang, H., Coggins, N.B., Lott, P., Estrada, A., Toal, T., Arana, A.M., Polanco-Echeverry, G., Rocha, S., A. -H., M., Mitsiades, N., Kaochar, S., O'Malley, B.W., Ellis, M.J., Hilsenbeck, S.G., Ittmann, M., Corso, S., Fiori, A., Giordano, S., van de Ven, M., Peeper, D.S., Miller, I., Bernado, C., Morancho, B., Ramirez, L., Arribas, J., Palmer, H.G., Piris-Gimenez, A., Soucek, L., Dahmani, A., Montaudon, E., Nemati, F., Dangles-Marie, V., Decaudin, D., Roman-Roman, S., Alferez, D.G., Spence, K., Clarke, R.B., Bentires-Alj, M., Chang, D.K., Biankin, A.V., Bruna, A., O'Reilly, M., Caldas, C., Casanovas, O., Gonzalez-Suarez, E., Munoz, P., Villanueva, A., Conte, N., Mason, J., Thorne, R., Meehan, T.F., Parkinson, H., Dudova, Z., Krenek, A., Stuchlik, D., Elemento, O., Inghirami, G., Golebiewska, A., Niclou, S.P., Wisman, G.B.A., de Jong, S., Kralova, P., Sedlacek, R., Claeys, E., Leucci, E., Borsani, M., Lanfrancone, L., Pelicci, P.G., Maelandsmo, G.M., Norum, J.H., Vinolo, E., Serra, V.

Publikováno v: Nature Genetics
bioRxiv
PDXNET Consortium, EurOPDX Consortium, Alferez-Castro, D, Spence, K, Clarke, R & et al. 2021, ' Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts ', Nature Genetics, vol. 53, no. 1, pp. 86-99 . https://doi.org/10.1038/s41588-020-00750-6

Patient-derived xenografts (PDXs) are resected human tumors engrafted into mice for preclinical studies and therapeutic testing. It has been proposed that the mouse host affects tumor evolution during PDX engraftment and propagation, affecting the ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::636839fdd226e1a6cf4dfbb55f18ac93
https://doi.org/10.1038/s41588-020-00750-6

Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma.

Autor: Zacarías-Fluck MF; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; lsoucek@vhio.net mzacarias@vhio.net., Massó-Vallés D; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain., Giuntini F; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., González-Larreategui Í; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Department of Cellular Biology, Phisiology, and Immunology, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallés, Spain., Kaur J; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Casacuberta-Serra S; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain., Jauset T; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain., Martínez-Martín S; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain., Martín-Fernández G; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain., Serrano Del Pozo E; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Foradada L; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain., Grueso J; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain., Nonell L; Bioinformatics Unit, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain., Beaulieu ME; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain., Whitfield JR; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Soucek L; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; lsoucek@vhio.net mzacarias@vhio.net.; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), 08035 Barcelona, Spain.

Publikováno v: Genes & development [Genes Dev] 2023 Apr 01; Vol. 37 (7-8), pp. 303-320. Date of Electronic Publication: 2023 Apr 06.

Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma

Autor: Ikemori, R. (Rafael), Gabasa, M. (Marta), Duch, P. (Paula), Vizoso, M. (Miguel), Bragado, P. (Paloma), Arshakyan, M. (Marselina), Luis, I.C. (Iuliana-Cristiana), Marín, A. (Albert), Morán, S. (Sebastian), Castro, M. (Manuel), Fuster, G. (Gemma), Gea-Sorli, S. (Sabrina), Jauset, T. (Toni), Soucek, L. (Laura), Montuenga-Badia, L.M. (Luis M.), Esteller, M. (Manel), Monsó, E. (Eduard), Peinado, V.I. (Victor Ivo), Gascon, P. (Pere), Fillat, C. (Cristina), Hilberg, F. (Frank), Reguart, N. (Noemi), Alcaraz, J. (Jordi)

The tumor-promoting fibrotic stroma rich in tumor-associated fibroblasts (TAF) is drawing increased therapeutic attention. Intriguingly, a trial with the antifibrotic drug nintedanib in non– small cell lung cancer reported clinical benefits in aden

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1111::1b1659e5924926683c9ca9931e19b17e
https://hdl.handle.net/10171/66263